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Dendritic cells (DCs) have a key role in the regulation of immune response. We herein explored, in patients with inflammatory
diseases, the role of monocyte derived DC’s (mo-DCs) on the generation of Th17 and T regulatory (Treg) lymphocytes. Peripheral
blood was obtained from thirty-five patients with rheumatoid arthritis (RA), twelve with systemic lupus erythematosus (SLE), and
twenty healthy subjects. Mo-DCs were generated under standard (IL-4/GM-CSF) or tolerogenic (IL-4/GM-CSF plus recombinant
P-selectin or PD-1 or IL-10) conditions, and their ability to induce Th17 and Treg lymphocytes was tested. We detected that mo-
DCs from patients with RA showed an enhanced release of IL-6 and IL-23 as well as an increased capability to induce Th17 cells.
Although mo-DCs from SLE patients also released high levels of IL-6/IL-23, it did not show an increased ability to induce Th17
lymphocytes. In addition, mo-DCs, from patients with RA and SLE generated under the engagement of PSGL-1, showed a defective
capability to induce Foxp3+ Treg cells. A similar phenomenon was observed in SLE, when DC’s cells were generated under PDL-1
engagement. Our data indicate that DCs from patients with rheumatic inflammatory disease show an aberrant function that may
have an important role in the pathogenesis of these conditions.
1. Introduction
The defective regulation of the activation and proliferation
of auto-reactive T cells that are not deleted in the thymus
may result in different autoimmune disorders [1]. Initially,
several inflammatory autoimmune diseases were considered
to be entirely mediated by Th1 lymphocytes, which mainly
synthesize IL-2 and IFN-𝛾. However, in recent years, different
studies have demonstrated that Th17 lymphocytes also play
an important role in the pathogenesis of these conditions,
including multiple sclerosis, psoriasis, inflammatory bowel
disease, Hashimoto’s thyroiditis, and rheumatoid arthritis
[2–8]. In addition, Th17 cells and Th17 cytokines are also
involved in the pathogenesis of fibrotic autoimmune diseases
as primary biliary cirrhosis (PBC) and systemic sclerosis
(SSc) [9]. Th17 lymphocytes are a subset of CD4+ T cells
characterized by the synthesis of IL-17A, IL-21, and IL-22,
and the expression of IL-23R and CCR6 receptors [10]. Inter-
leukin IL-17A is a proinflammatory cytokine that induces
the synthesis of TNF-𝛼, IL-1𝛽, IL-6, IL-8, GM-CSF, different
metalloproteinases (MMP-1, -3, -9), chemokines (CCL2, 3),
and PGE2 by different cell types, including fibroblasts, epithe-
lial and endothelial cells, keratinocytes, osteoblasts, and
monocyte/macrophages [11–13]. In addition, in patients with
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rheumatoid arthritis (RA), IL-17 is involved in the destruction
of the extracellularmatrix and juxtaarticular bone resorption,
through the induction of synthesis of RANKL and matrix
metalloproteases [14, 15].
The differentiation of human Th17 lymphocytes is
induced by the combined action of different cytokines,
including IL-1𝛽, IL-6, and IL-23 [16], whereas IL-21 promotes
the survival and expansion of these cells [17, 18]. In addition,
TGF-𝛽 seems to also participate in the differentiation of
Th17 cells, which may have a conventional or a regulatory
phenotype [19, 20].
Dendritic cells (DCs) are professional antigen presenting
cells that play a key role in the induction and regulation of
T cell mediated responses [21]. Two main DC subsets have
been characterized in humans, myeloid, and plasmacytoid
DCs (mDCs, CD11c+, pDCs, and CD11c−) [22]. In addition,
when monocytes are cultured in the presence of GM-CSF
and IL-4, differentiate into a subset of mDCs (monocyte
derived DCs or MDDCs or mo-DCs) [23]. DCs express a
wide repertoire of membrane receptors, including pattern
recognition receptors (PRRs), which upon engagement by
their ligands (DAMPS and PAMPs) induce their terminal
differentiation and activation [21]. It has been described that a
subfamily of PRRs (C-type lectin receptors or CLRs) induce
the activation of Syk and CARD9 and preferentially induce
the polarization of naiveTh0 lymphocytes towardsTh17 cells
[24–26]. On the other hand, it has also been described that
tolerogenic DCs are able to inhibit the differentiation of naı¨ve
Th0 lymphocytes, suppressing thus the generation of T cell
mediated immune responses [27]. Conversely, tolerogenic
DCs are able to induce the generation of T regulatory (Treg)
lymphocytes [28]. In this regard, it has been described that
different membrane receptors (e.g., PSGL-1 and PDL-1) as
well as cytokines (e.g., IL-10) are able to induce the generation
of tolerogenic DCs [29, 30].
Rheumatoid arthritis (RA) is a systemic inflammatory
disease characterized by chronic synovial inflammation,
which results in cartilage and bone damage, leading to
joint destruction. Different cell types and their mediators
are involved in the tissue destructive inflammation seen
in this condition, including Th17 lymphocytes [31]. In this
regard, mice deficient in IL-17 show a decreased induction
of collagen induced arthritis (CIA) [32]. Accordingly, in this
animal model of RA, the neutralization of IL-17 reduces joint
inflammation, cartilage destruction, and bone erosion [33].
In humans, elevated concentrations of IL-17 have been found
in synovial fluid and in peripheral blood of RA patients
as well as a high proportion of Th17 lymphocytes in their
peripheral blood [34]. In fact, different data indicate that the
inflamed rheumatoid synovium is a tissue niche that greatly
favors the generation of Th17 cells [35]. Recently, Vaknin-
Dembinsky et al. showed that mo-DCs from patients with
multiple sclerosis show an enhanced synthesis of IL-23 as well
as an increased ability to induce the in vitro differentiation of
Th17 lymphocytes [36]. However, the precise role of IL-23 and
DCs on the induction ofTh17 cells in patients with RAhas not
been fully characterized.
SLE is an autoimmune, systemic, inflammatory condition
with many different immunologic aberrations, including
an enhanced synthesis of IL-10 and type I interferon, a
diminished function of natural Treg lymphocytes, and an
aberrant phenotype and function of DCs [37]. As in the case
of RA, different reports indicate that Th17 lymphocytes are
involved in the pathogenesis of SLE, including lupus nephritis
[38, 39]. We have herein studied the role of immunogenic
and tolerogenic DCs on the in vitro induction of Th17
cells and Treg lymphocytes in patients with RA and SLE.
We detected that mo-DCs from patients with RA show an
enhanced release of IL-6/IL-23 and an increased capability
to induce Th17 cells. On the other hand, tolerogenic mo-
DCs from patients with RA and SLE showed a defective
capability to induce the generation of Foxp3+ Treg cells.
These results further support the important role of DCs
in the pathogenesis of autoimmune diseases, and indicate
that it is interesting to comparatively evaluate the generation
of effector and regulatory lymphocytes in these conditions
[9].
2. Materials and Methods
2.1. Patients. Thirty-five female patients with RA, with a
mean age of 42.3 years, diagnosed according to the criteria
of the American College of Rheumatology (ACR) [40] were
included in the study. Fifteen patients were untreated at the
time of their inclusion in the study, and their mean Disease
Activity Score 28 (DAS28) was 4.09. The remaining patients
(with a mean DAS28 of 3.45) were under therapy with
disease-modifying antirheumatic drugs (DMARDs), receiv-
ing mainly low-dose methotrexate (14.9 ± 3.8mg/week) and
sulfasalazine (1.4 ± 0.7 g/day). Twelve female patients with
SLE, according to the classification criteria of the American
College of Rheumatology [41], were also studied. Their mean
age was 33.1 years (range: 16–39), and the mean duration of
disease was 19 months. All these patients were not receiving
immunosuppressive drugs at the time of the study, and eight
of them had active disease, with a MEX-SLEDAI score >3.0
[42]. Three patients were under therapy with low doses of
prednisone (10–20mg/day), and two were receiving hydrox-
ychloroquine (200mg/day). No patients with renal failure
were included. No patients under therapy with biological
agents were included in the study. Twenty female healthy
individuals with a mean age 35.5 years were included as
controls. This study was approved by the local University
Ethics Committee and all subjects signed an informed
consent.
2.2. Cells. Peripheral blood mononuclear cells (PBMC) were
isolated from heparinized venous blood by Ficoll-Hypaque
density gradient centrifugation (Sigma-Aldrich, St. Louis,
MO). Monocytes and CD4+ T cells were positively isolated
from PBMC by using MicroBeads (Miltenyi Biotec) coupled
to mAbs, according to manufacturer’s instructions. The
purity of the isolated cells was verified by flow cytometry
analysis and was always greater than 95%. After CD4+ T
cells isolation, cells were incubated in complete RPMI culture
medium with 2% of fetal calf serum (FCS) until they were
used in coculture assays.
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2.3. Generation of Monocyte-Derived Dendritic Cells (mo-
DC). Monocytes (1 × 106/mL) were plated in RPMI-1640
culture medium supplemented with 10% FCS, 2.0mM L-
glutamine, 100U/mL penicillin, 100𝜇g/mL streptomycin
(GibcoBRL,Grand Island,NY), 1% sodiumpyruvate (Gibco),
1% nonessential amino acids (Hyclone Laboratories, South
Logan, UT), and 50mM 2-mercaptoethanol (Gibco) in the
presence of 200 ng/mL rhGM-CSF and 15 ng/mL rhIL-4
(eBiosciences) at 37∘C and 5% of CO
2
. Cells were fed on
days 2 and 4 by changing one half of the medium and
keeping the same concentration of IL-4 and GM-CSF. At
day 6, DCs were induced to mature by adding 200 ng/mL
of LPS (Sigma-Aldrich). Forty-eight hours after stimulation,
supernatants were collected for cytokine measurement. In
the case of the induction of tolerogenic dendritic cells, the
differentiation of monocytes was carried out in 24-well tissue
culture plates previously coated with recombinant human
P-selectin (10 𝜇g/mL) or PD1 (2.5 𝜇g/mL) (BioLegend, San
Diego, CA) by overnight incubation at 4∘C. In other set of
experiments, monocytes were induced to differentiate in the
presence of IL-10 (40 ng/mL, Biolegend).
2.4. Lymphocyte-DC CoCultures and Induction of Th17 and
Treg Differentiation. For the induction of differentiation of
Th17 cells, mature mo-DC and autologous CD4+ T cells
were cocultured in 24-well plates at 1 : 10 ratio in complete
Iscove’s modified Dulbecco medium (IMDM, Gibco BRL).
Plates were previously coated with 10 𝜇g/mL anti-CD3 (eBio-
sciences) and anti-CD28 (Immunotech) mAbs, and Th17
differentiation was induced by adding rhIL-23 (10 ng/mL,
R&D systems, Minneapolis, MN), IL-6 (50 ng/mL), IL-1𝛽
(10 ng/mL), IL-21 (50 ng/mL), TNF-𝛼 (10 ng/mL, all from
eBiosciences), and anti-IL-4 and anti-IFN-𝛾mAbs (5 𝜇g/mL,
BioLegend). Under such conditions, cells were cultured
during 5 days at 37∘C and 5% of CO
2
, and then the percent
of Th1 andTh1/Th17 cells was determined by flow cytometry.
In the case of the induction of Th1/Th17 cells, no anti-IFN-𝛾
antibodywas added. For induction of Treg cell differentiation,
DCs generated in the presence of tolerogenic stimuli (IL-
10, PD1, P-selectin) were cocultured with autologous CD4+
T cells for five days, and then cells were immunostained
for CD4, CD25, and Foxp3, and they were analyzed by flow
cytometry.
2.5. Flow Cytometry Analysis. Myeloid and plasmacytoid
dendritic cells were analyzed by using a mixture of mAbs
specific for lineage markers combined with HLA-DR, CD11c,
BDCA-2, and BDCA-4 mAbs. The following antibodies were
used: FITC labeled anti-CD3, anti-CD14, anti-CD16, anti-
CD19, and anti-CD56 (eBiosciences); HLA-DR-APC-Cy7,
CD11c-PercPCy5.5 (BioLegend), BDCA-2-APC and BDCA-
4-APC (Miltenyi Biotec). Cells were analyzed in a FACSAria
II flow cytometer (Becton Dickinson, San Jose´, CA) using the
FACSDiva software.
For intracellular cytokine analysis, cells were treated for
5 hours with PMA plus Ionomycin (50 ng/mL, and 1 𝜇g/
mL, resp., Sigma-Aldrich) and with Brefeldin A (1 𝜇g/mL,
Cytofix/Cytoperm kit, eBioscience) for the last 2 hours.Then,
cells were stained for the indicated cell surface markers,
fixed, permeabilized (Cytofix/Cytoperm kit, eBiosciences),
and labeled for IL17 (anti-IL-17-PE, R&D Systems) and IFN-
𝛾 (anti-IFN-𝛾-FITC, eBiosciences) for 30min at 4∘C. Cells
were analyzed in a FACSCalibur flow cytometer (Becton-
Dickinson) using the CellQuest Pro software.
Cell surface markers of mo-DCs were analyzed with
mAbs directed against CD83, CD86, PSGL-1, PDL-1 (eBio-
sciences), and HLA-DR (BD Pharmingen). In all analyzes,
Fc𝛾 receptors were blocked (Fc𝛾R binding inhibitor, eBio-
sciences) before immunostaining.
2.6. Cytokine Quantification. Levels of IL-23, IL-1𝛽, IL-6, IL-
22, IL-17A, and IFN-𝛾 were quantified in cell-free super-
natants using Human ELISA kits (eBiosciences and PEPRO-
TECH) according to manufacturer’s instructions. All deter-
minations were performed by duplicate, and plates were
analyzed by using a Multiskan ELISA reader.
2.7. Statistical Analyses. Differences between two groups
were determined using the Student’s 𝑡 test or Mann-Whitney
𝑈 test. One and two way analysis of variance with the proper
post hoc analysis was performed when necessary. Data were
analyzed using the GraphPad Prism software (GraphPad, San
Diego, CA).
3. Results
3.1. Peripheral Blood DC Subsets and mo-DCs in Patients with
RA and SLE. We first analyzed the levels of DCs subsets in
the peripheral blood from patients and controls. As shown in
Figure 1(a), patients with RA and SLE showed an enhanced
proportion of CD11c+ BDCA-2+ myeloid DCs (𝑃 < 0.05 in
both cases). Furthermore, patients with SLE exhibited higher
levels of CD11c− BDCA-4+ plasmacytoid DCs compared to
both healthy controls and patients with RA (𝑃 < 0.05 in both
cases). However, no apparent association between disease
activity or immunosuppressive therapy and DCs levels was
detected in patients with SLE or RA (data not shown). As
shown in Figure 1(b), the peripheral bloodmyeloidDCs from
patients with RA and SLE exhibited an enhanced expression
of the regulatory receptors PSGL-1 and PDL-1 (𝑃 < 0.05
in all cases, compared to healthy controls). In the case of
plasmacytoid DCs, although the expression of PDL-1 tended
to be higher in patients with RA and SLE, no significant
differences were observed compared to controls (𝑃 > 0.05 in
both cases, Figure 1(b)). In contrast, the expression of PSGL-1
was significantly higher in plasmacytoid DCs from patients
with RA and SLE compared to cells from healthy subjects
(𝑃 < 0.05 in both cases, Figure 1(b)).
We then generated in vitro mo-DCs under standard
conditions with IL4/GM-CSF. As shown in Figure 1(c), and
as we have previously reported [43], in the case of SLE, these
myeloid DCs exhibited a diminished density of expressions
of CD80, CD86, and HLA-DR (measured as their MFI). In
contrast, the phenotype of mo-DCs was similar in patients
with RA and healthy controls. In addition, a similar pattern
of PSGL-1 and PDL-1 expression was observed in mo-DCs
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Figure 1: Peripheral bloodDCs subsets andmo-DCs in patients with RA and SLE. (a)Myeloid and plasmacytoid DCs levels were determined
in freshly isolated peripheral bloodmononuclear cells bymultiparametric flow cytometry, as stated inmaterials andmethods.Data correspond
to the percent of CD11c+ BDCA-2+ nonlineage cells (myeloid DCs), and CD11c− BDCA-4+ nonlineage cells (plasmacytoid DCs). (b) The
expression of the regulatory receptors PSGL-1 and PD-1 bymyeloid and plasmacytoidDCswas analyzed bymultiparametric flow cytometry in
blood samples from patients with RA and SLE, as stated inmaterials andmethods. (c) mo-DCs were generated in vitro by culturing peripheral
blood monocytes in the presence of IL-4 and GM-CSF, and their maturation was induced by LPS. Then, cells were immunostained for the
indicated molecules, and analyzed by flow cytometry. Data correspond to the percent of positive cells (left panel), and mean fluorescence
intensity (MFI, right panel) in cells from representative patients with RA and SLE, and a healthy control. (d) IL-1𝛽, IL-6 and IL-23 were
quantified in the cell culture supernatants of mo-DCs incubated in the presence of LPS. Median and interquartile range are shown in (a) and
(d) and the arithmetic mean and SD in (c). ∗𝑃 < 0.05. In all panels, white boxes correspond to controls, grey light boxes to patients with RA,
and grey dark boxes to SLE patients.
from the patients included in this study (data not shown).
On the other hand, when different cytokines were measured
in the cell culture supernatants of mo-DCs, we observed an
enhanced release of IL-6 and IL-23 by cells from patients with
RA and SLE, compared to healthy individuals (𝑃 < 0.05 in all
cases, Figure 1(d)). In contrast, similar concentrations of IL-
1𝛽were detected in the cell culture supernatants frompatients
and controls (𝑃 > 0.05, Figure 1(d)).
3.2. Effect of DCs on the In Vitro Differentiation of Th17 Lym-
phocytes. Wefirst analyzed by flow cytometry the proportion
of Th17 cells in the PBMC of healthy controls and patients.
As shown in Figure 2, patients with RA and SLE showed
enhanced levels of CD4+ IL-17A+ lymphocytes compared
to controls (𝑃 < 0.05 in both cases). In addition, the
percentage of Th1/Th17 lymphocytes (defined as CD4+ IL-
17A+ IFN-𝛾+) was also higher in patients with RA or SLE
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Figure 2: Quantification of Th17 cells in the peripheral blood from patients with RA and SLE. Peripheral blood mononuclear cells from
patients with RA and SLE and healthy controls were immunostained for the determination of Th17 (CD4+ IL-17A+) and Th1/Th17 (CD4+
IL-17A+ IFN-𝛾+) lymphocytes, and analyzed by flow cytometry, as stated in materials and methods. Dot plots from cells of a representative
patient with RA and a healthy control are shown in (a), and the median and interquartile range of the percent of positive cells in (b). Numbers
in quadrants correspond to the percent of events. ∗𝑃 < 0.05.
compared to healthy subjects (𝑃 < 0.05 in both cases).
Similar results were observed in the case of CD4(−) IL-17+
lymphocytes (𝑃 < 0.05 in both cases, data not shown).
Interestingly, patients with RA under therapy with DMARDs
showed significantly lower levels of Th17 cells compared to
untreated patients (𝑃 < 0.05, data not shown). However,
no significant correlation between disease activity (DAS28
score) and Th17 levels was detected in these patients (𝑟 =
0.17, 𝑃 > 0.05, data not shown). In contrast, a significant
correlation between SLEDAI score and Th17 percentages
was observed in patients with SLE (𝑟 = 0.39, 𝑃 < 0.05,
data not shown) .
When the mo-DCs from patients with RA were cocul-
turedwith autologousCD4+T cells, we detected an enhanced
generation of Th17 (CD4+ IL-17A+) lymphocytes (𝑃 <
0.05 compared to controls, Figure 3(a)). As expected, this
phenomenon was enhanced when cells were cultured under
Th17 polarizing conditions (addition of IL-1, IL-6, IL-21,
and TNF-𝛼, with blockade of IL-4 and IFN-𝛾, Figure 3(a)).
However, although the addition of IL-23 alone tended to have
a similar effect, no significant differences between RA and
controls were reached (𝑃 > 0.05, Figure 3(a)). Furthermore,
similar levels of Th17 induction were observed in cells from
patients with SLE and controls, in the different conditions
tested (𝑃 > 0.05 in all cases, Figure 3(a)). Finally, although
cell cocultures frompatients with RA and SLE tended to show
an increased generation of Th1/Th17 lymphocytes (CD4+ IL-
17A+ IFN-𝛾+), no significant differences were observedwhen
compared to cells from healthy controls (𝑃 > 0.05 in all
cases, Figure 3(b)). In agreement with the above results, we
observed a significant enhanced release ofTh17 cytokines (IL-
17A and IL-22) in the mo-DC/T lymphocyte cocultures from
patients with RA (Figure 4).
3.3. Effect of Tolerogenic DCs on the Induction of Treg Lympho-
cytes. An additional analysis of the functional status of
mo-DCs in SLE and RA was performed, by measuring
their capability to induce Treg lymphocytes. When mo-
DCs were generated under standard conditions (IL-4/GM-
CSF), those derived from SLE patients showed a diminished
capability to induce the generation of autologous CD4+
CD25+ Foxp3+ Treg cells (𝑃 < 0.05 compared to controls,
Figure 5). Interestingly, when mo-DCs were generated under
the engagement of the tolerogenic receptor PSGL-1 (by the
addition of exogenous P-selectin), a diminished capability to
promote the generation of Treg lymphocytes was observed
in patients with RA and SLE (𝑃 < 0.05 compared to
controls, in both cases, Figure 5). A similar phenomenon was
observed in the case ofmo-DCs frompatientswith SLE,when
they were generated in the presence of recombinant PD-1
(𝑃 < 0.05 compared to controls, Figure 5). Althoughmo-DCs
from patients with RA generated under PDL-1 engagement
tended to show a diminished ability to induce Treg cells, no
significant difference was reached in this case (𝑃 > 0.05,
Figure 5).
4. Discussion
Different data indicate that in the complex pathogenesis of
RA and SLE, DCs as well as Th17 and Treg lymphocytes have
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Figure 4:Th17 cytokine synthesis by cocultures ofDCs andCD4+ lymphocytes in patients with RA and SLE. IL-17A and IL-22were quantified
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an important role [8, 31, 36]. In this work, we first analyzed
the levels of Th17 lymphocytes and the two main subsets of
peripheral blood DCs in samples from these patients and
healthy controls. In agreement with previous reports [12, 44,
45], and as has been observed in other conditions such as PBC
or SSc [9], we detected enhanced levels of Th17 lymphocytes
in the peripheral blood from patients with RA and SLE.
However, it is of interest that other authors have not observed
increased numbers of these T helper cells in patients with RA
[43]. It is feasible that these apparent contradictory results
could be due to differences in the therapy, time of disease
evolution, level of disease activity or genetic background of
patients. In this regard, we have detected that those patients
under therapy with DMARDs exhibit lower percentages of
Th17 cells than those in untreated patients. In addition, we
found a significant association between disease activity and
Th17 cell levels in patients with SLE.However, in patients with
RA this correlation was not detected. All these data indicate
that it would be interesting to perform a longitudinal study of
Th17 cell levels in a cohort of patients with RA and SLE.
In order to further explore the role of DCs in the induc-
tion of Th17 lymphocytes in patients with RA and SLE, we
performed in vitro experiments with mo-DCs. In this regard,
it is worth mentioning that although this type of DCs is not
detected in the peripheral blood of healthy subjects, different
evidences indicate that this subset of antigen presenting cells
is generated in vivo [46]. Our results indicate that the mo-
DCs from patients with RA have an increased capability to
induce the in vitro differentiation of Th17 lymphocytes as
well as an enhanced potential to release cytokines that allow
the generation of these cells. These data further support the
important role of DCs in the pathogenesis of RA and indicate
that this functional feature is preserved during their in vitro
generation from peripheral blood monocytes. In addition,
our results also support that the inflamed rheumatoid syn-
ovium is a privileged site for the generation of Th17 cells
[35]. Since this enhanced capability of mo-DCs to induce
Th17 lymphocytes was not observed in patients with SLE,
our data indicate that, under our experimental conditions,
the overproduction of IL6/IL-21/IL-23 by DCs is not enough
to increase the differentiation of Th17 lymphocytes. In this
regard, it is of interest that we have corroborated [47] that
mo-DCs from patients with SLE show a defective expression
of HLA-DR and the costimulatory molecule CD86. Thus,
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Figure 5: Induction of Treg lymphocytes by mo-DCs from patients
withRAand SLE.Monocyte derivedDCs generated under tolerizing
conditions (PDL-1, PSGL-1 engagement, or IL-10 addition) or not,
were cocultured with autologous CD4+ lymphocytes for five days.
Then, the percent of CD4+ CD25+ Foxp3+ lymphocytes was
determined by flow cytometry. Data correspond to the median and
interquartile range of the percent of positive cells. ∗𝑃 < 0.05.
it is feasible that this defective phenotype of SLE mo-DCs
accounts, at least in part, for their diminished ability to induce
Th17 cells, compared to cells from patients with RA.
We have detected that the levels of peripheral blood
mDCs are enhanced in patients with RA, and this finding is
in disagreement with a previous report [48]. As in the case
of Th17 cells, it is feasible that different factors could account
for this apparent contradictory results. In this regard, it seems
evident that the levels of DCs in peripheral blood are strongly
influenced by their rates of generation in bone marrow and
their extravasation to different tissues, phenomena that are
not easy to analyze in vivo, in human beings. Thus, we
consider that it would be easy and interesting to perform a
prospective study on the levels of the different DC subsets in
the peripheral blood in patients with RA and SLE.
Patients with RA and SLE show a defective function
of nTreg cells, and abnormal numbers and proportions of
Treg lymphocytes have been reported in these patients [49–
51]. Since DCs have an important role in the generation of
induced Treg (iTreg) cells, we decided to generate in vitro
tolerogenic DCs and test their ability to trigger the differ-
entiation of these regulatory lymphocytes. We have detected
that upon engagement of the tolerogenic receptor PSGL-1, the
mo-DCs from patients with RA and SLE showed a defective
capability to induce the generation of iTreg cells.We consider
that this is an interesting finding since further supports the
important role of DCs in the defective immune-regulation
observed in these patients. In addition, it is also of interest
that this aberrant functional feature is observed after their in
vitro differentiation fromperipheral bloodmonocytes. In this
regard, it would be of interest to determine whether this type
ofmo-DCs are generated in vivo, in patientswithRAand SLE,
in their diseased, and to explore their possible contribution
to the defective regulation of the inflammatory phenomenon.
The possible cause of the enhanced expression of PSGL-1 and
PDL-1 by the mo-DCs from these patients also remains as an
interesting point to be explored.
Since it has been previously reported that patients with
SLE and RA show an enhanced synthesis of IL-10 [36, 52],
it is of interest that this cytokine had showed a tolerogenic
effect on mo-DCs that was not significantly different from
that found in patients compared to controls.Thus, this finding
suggests that although the overproduction of IL-10 may
contribute to the pathogenesis of SLE and RA [37, 52]. It
is also feasible that the enhanced synthesis of this cytokine
could favour the generation of tolerogenic DCs in vivo in
these patients. In contrast, our findings indicate that the other
tolerogenic stimulus employed in this study (PD-1) is not able
to exert a significant effect on themo-DCs from patients with
SLE.This finding further suggests that the defective immune-
regulatory function observed in patients with SLE is the result
of many different factors, including the diminished activity of
several tolerogenic receptors expressed by DCs.
5. Conclusions
Our findings strongly suggest that mo-DCs may significantly
contribute to the enhanced generation of Th17 lympho-
cytes, and the diminished number and activity of Treg cells
observed in patients with RA and SLE. Thus, the possible
functional role of this subset of DCs in vivo, in the pathogene-
sis of autoimmune inflammatory conditions, is an interesting
point to be further explored.
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